|
Market Closed -
Australian S.E.
02:10:28 2026-09-28 EDT
|
5-day change | 1st Jan Change | ||
| 0.3300 AUD | 0.00% |
|
-4.35% | -49.23% |
| 08-31 | Recce Pharmaceuticals Ltd Reports Earnings Results for the Full Year Ended June 30, 2026 | CI |
| 08-30 | Recce Pharmaceuticals Ltd Auditor Raises 'Going Concern' Doubt | CI |
| Market Cap | 101M 70.82M 62.26M 58.9M 53.38M 100M 6.8B 705M 272M 3.47B 266M 260M 11.15B | P/E 2027 * |
-3.88x | P/E 2028 * | 2.97x |
|---|---|---|---|---|---|
| Enterprise Value | 126M 88.34M 77.66M 73.47M 66.58M 125M 8.48B 880M 339M 4.33B 332M 324M 13.9B | EV / Sales 2027 * |
10.1x | EV / Sales 2028 * | 0.97x |
| Free-Float |
62.73% | Yield 2027 * |
-
| Yield 2028 * | - |
Australian S.E.AUD
| Markets | Quality | ||
|---|---|---|---|
Australian S.E.
| RCE | Delayed | |
Tradegate
| R9Q | Real-time | |
|
Deutsche Boerse AG
| R9Q | Delayed | |
|
Börse Stuttgart
| R9Q | Delayed | |
|
Boerse Muenchen
| R9Q | Real-time |
| 1 week | -4.35% | ||
| Current month | -12.00% | ||
| 1 month | -12.00% | ||
| 3 months | -17.50% | ||
| 6 months | -30.53% | ||
| Current year | -49.23% |
| 1 week | 0.32 |  | 0.34 |
| 1 month | 0.32 | | 0.38 |
| Current year | 0.32 | | 0.73 |
| 1 year | 0.32 | | 0.73 |
| 3 years | 0.28 | | 0.73 |
| 5 years | 0.28 | | 1.38 |
| 10 years | 0.13 | | 1.88 |
| Manager | Title | Age | Since |
|---|---|---|---|
James Graham
CEO | Chief Executive Officer | - | 2020-08-27 |
Justin Reynolds
DFI | Director of Finance/CFO | - | - |
Michele Dilizia
CTO | Chief Tech/Sci/R&D Officer | - | 2020-09-29 |
| Director | Title | Age | Since |
|---|---|---|---|
Michele Dilizia
BRD | Director/Board Member | - | 2012-09-30 |
James Graham
BRD | Director/Board Member | - | 2012-04-30 |
| Director/Board Member | - | 2022-08-31 |
| Date | Insider | Type | Main position | Quantity | % Market Cap. | Importance |
|---|---|---|---|---|---|---|
| 7/31/26 | Buy | Chief Executive Officer | 25,000 | 0.0083% | ||
| 7/31/26 | Buy | Director | 75,000 | 0.0250% | ||
| 7/31/26 | Buy | Director | 37,500 | 0.0125% |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | 0.00% | -4.35% | -22.35% | -27.47% | 70.86M | |
| +0.11% | +2.76% | +63.52% | +115.51% | 1,055B | |
| +0.27% | +0.73% | +51.33% | +73.10% | 654B | |
| +0.73% | +0.88% | +20.70% | +73.89% | 467B | |
| -1.36% | -0.39% | +40.20% | +41.03% | 348B | |
| +1.34% | +5.47% | +23.37% | +31.30% | 275B | |
| -0.48% | -0.06% | +13.56% | +12.36% | 258B | |
| +0.85% | +8.42% | +53.17% | +55.45% | 224B | |
| +0.85% | +1.40% | +35.78% | +101.47% | 187B | |
| -0.30% | -10.41% | -27.62% | -61.04% | 171B | |
| Average | +0.13% | +0.23% | +25.17% | +41.56% | 363.84B | |
| Weighted average by Cap. | +0.14% | +1.32% | +40.69% | +69.05% |
| 2027 * | 2028 * | |
|---|---|---|
| Net sales | 12.5M 8.77M 7.71M 7.29M 6.61M 12.43M 842M 87.34M 33.69M 430M 32.92M 32.21M 1.38B | 54.3M 38.11M 33.5M 31.69M 28.72M 54.01M 3.66B 380M 146M 1.87B 143M 140M 6B |
| Net income | -25.1M -17.61M -15.49M -14.65M -13.28M -24.97M -1.69B -175M -67.67M -864M -66.13M -64.69M -2.77B | 33.4M 23.44M 20.61M 19.49M 17.67M 33.22M 2.25B 233M 90.05M 1.15B 88M 86.09M 3.69B |
| Net Debt | 24.96M 17.52M 15.4M 14.57M 13.21M 24.83M 1.68B 174M 67.31M 859M 65.77M 64.35M 2.76B | -48.1M -33.76M -29.68M -28.08M -25.44M -47.85M -3.24B -336M -130M -1.66B -127M -124M -5.31B |
Employees
-
Sector
Pharmaceuticals
| Date | Price | Change | Volume |
|---|---|---|---|
| 26-09-28 | A$0.3300 | 0.00% | 38,272 |
| 26-09-25 | A$0.3300 | 0.00% | 74,377 |
| 26-09-24 | A$0.3300 | -1.49% | 154,673 |
| 26-09-23 | A$0.3350 | +3.08% | 43,877 |
| 26-09-22 | A$0.3250 | -4.41% | 42,970 |
Annual profits - Rate of surprise
- Stock Market
- Stocks
- RCE Stock
Select your edition
All financial news and data tailored to specific country editions
